[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345808-105":59,"doc-detail-345808-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","assessing-the-treatment-of-pancreatic-ductal-adenocarcinoma-by-deuterium-metabolic-imaging-a-preclinical-study","Assessing the treatment of pancreatic ductal adenocarcinoma by deuterium metabolic imaging - a preclinical study","","Purpose evaluates the utility of Deuterium Metabolic Imaging (DMI) for monitoring pancreatic ductal adenocarcinoma progression and assessing therapeutic efficacy of cyclophosphamide (CP). Methods use C57BL mice bearing a PDAC model, comparing an untreated control cohort with a CP-treated cohort; 2H MRSI at 15.2T tracks deuterated glucose metabolism into lactate over weeks. Results show CP reduces tumor growth and improves survival, with DMI-linked correlations disrupted after treatment. Conclusion CP alters glucose metabolic kinetics in PDAC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessing-the-treatment-of-pancreatic-ductal-adenocarcinoma-by-deuterium-metabolic-imaging-a-preclinical-study/345808/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessing-the-treatment-of-pancreatic-ductal-adenocarcinoma-by-deuterium-metabolic-imaging-a-preclinical-study/345808.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does Deuterium Metabolic Imaging (DMI) evaluate in this study?","Question",{"text":112,"@type":113},"DMI is used to monitor disease progression and to assess the therapeutic efficacy of cyclophosphamide in pancreatic ductal adenocarcinoma by tracking metabolic changes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the PDAC model and treatment designed?",{"text":117,"@type":113},"C57BL mice were implanted with a PDAC model and divided into an untreated control group and a cyclophosphamide-treated group.",{"name":119,"@type":110,"acceptedAnswer":120},"What metabolic relationship changes after cyclophosphamide treatment?",{"text":121,"@type":113},"After CP treatment, tumor growth rates become statistically uncorrelated with glucose uptake and with lactate production (normalized to tumor size), indicating disrupted metabolic kinetics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345808,1790453967,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Magnetic Resonance Materials in Physics, Biology and Medicine (2026) 39:417–430  \n[https://doi.org/10.1007/s10334-026-01340-z](https://doi.org/10.1007/s10334-026-01340-z)  \nAssessing the treatment of pancreatic ductal adenocarcinoma by deuterium metabolic imaging: a preclinical study  \nElton T. Montrazi1 · Maya Kovalevsky1 · Keren Sasson2 · Lilach Agemy2 · Avigdor Scherz2 · Lucio Frydman1  \nReceived: 30 September 2025 / Revised: 1 March 2026 / Accepted: 4 March 2026 / Published online: 6 April 2026 © The Author(s) 2026  \nAbstract  \nPurpose To evaluate the utility of Deuterium Metabolic Imaging (DMI) as a tool for monitoring disease progression and assessing the therapeutic efficacy of cyclophosphamide in pancreatic ductal adenocarcinoma (PDAC) .  \nMethods The study utilized C57BL mice implanted with a PDAC model, and separated into two experimental groups: One cohort served as an untreated control, while the second was treated with the chemotherapeutic agent cyclophosphamide (CP). Metabolic mapping for the two cohorts was performed over the course of weeks using 2H MRSI at 15.2T, tracking the metabolic pathway of deuterated glucose as it converts by the PDAC into lactate.  \nResults CP administration led to a significant reduction in tumor growth and improved survival rates compared to the control group. Tumor growth rates for the untreated, control group, showed a strong inverse correlation for glucose’s uptake anda strong direct correlation with the glucose-to-lactate conversion rates as seen by DMI. CP treatment disrupted both these correlations: Post-treatment, tumor growth rates became statistically uncorrelated with either glucose consumption or lactate production which, when normalized for tumor size, remained relatively constant during the treatment period.  \nConclusion The study demonstrates that CP treatment fundamentally alters the metabolic kinetics of glucose in PDAC tumors, inducing disruptions in metabolic correlations that may serve for distinguishing therapeutic success from failure.  \nKeywords Pancreatic cancer · 2H MRSI · Anaerobic glycolysis · Warburg effect · Cyclophosphamide treatment · Biomarking  \nIntroduction  \nPancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality. [1] In Israel, the United States and in many European countries, pancreatic cancer is currently the 3rd most common cause of cancer-related deaths; [2] given present trends and the progress happening in the diagnosis of more widespread kinds of cancers—breast, prostate, lung, colon—PDAC is expected to become the second deadliest cancer during the 2030s. [3] PDAC’s five-year survival expectancy has improved over the last decades, but still stands at a dismal rate of ≈20% . One of the reasons making PDAC such a deadly cancer is the dearth  \n* Lucio Frydman [lucio.frydman@weizmann.ac.il](lucio.frydman@weizmann.ac.il)  \n1 Department of Chemical and Biological Physics, Weizmann Institute of Science, Rehovot, Israel  \n2 Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel  \nof reliable early diagnosis methods. This is compounded by the paucity of treatment options, and of reliable reporters attesting, early into the treatment, the success or lack thereof for a chosen route of action. Thus, while diagnostic and treatment alternatives have improved for many cancers, they have remained remarkably poor and ambiguous for PDAC. Transabdominal and intraductal ultrasound; endoscopic cholangiopancreatography; contrast-enhanced CT; T 1, T2 and diffusion-weighted MRI; and MR cholangiopancreatography (MRCP), are all regularly used in assessing this disease—but they all find themselves lacking in terms of early detection. [4–7] 18F-FDG-based PET is also regularly used, but foremost to reveal metastases. All these imaging modalities also suffer from potential confounding factors, including benign lesions, inflammations and cysts. Coupled to this is PDAC’s dense stroma, decreasing further ","cbCait6kI4wwx6kO","https://ap.wps.com/l/cbCait6kI4wwx6kO","pdf",3557412,14,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What does Deuterium Metabolic Imaging (DMI) evaluate in this study?\",\"answer\":\"DMI is used to monitor disease progression and to assess the therapeutic efficacy of cyclophosphamide in pancreatic ductal adenocarcinoma by tracking metabolic changes.\"},{\"question\":\"How was the PDAC model and treatment designed?\",\"answer\":\"C57BL mice were implanted with a PDAC model and divided into an untreated control group and a cyclophosphamide-treated group.\"},{\"question\":\"What metabolic relationship changes after cyclophosphamide treatment?\",\"answer\":\"After CP treatment, tumor growth rates become statistically uncorrelated with glucose uptake and with lactate production (normalized to tumor size), indicating disrupted metabolic kinetics.\"}]","Assessing the treatment of pancreatic ductal adenocarcinoma by deuterium metabolic imaging - a preclinical study | PDF",1790058958,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c53f00cbdda17b66499996ee15426af4.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2c9e9ec4208fdf6914e498a41a57e7a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/676a0754e5665ad44b3363ed99387bc1.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62c9bef20734b672ba531eab58a9d519.webp",980,1301]